Generic placeholder image

Current Protein & Peptide Science

Editor-in-Chief

ISSN (Print): 1389-2037
ISSN (Online): 1875-5550

Review Article

Chemotherapeutic Drugs and Plasma Proteins: Exploring New Dimensions

Author(s): Mohammad Khalid Zia, Tooba Siddiqui, Syed Saqib Ali, Ahmed Abdur Rehman, Haseeb Ahsan and Fahim Halim Khan*

Volume 19, Issue 10, 2018

Page: [937 - 947] Pages: 11

DOI: 10.2174/1389203718666171002115547

Price: $65

Abstract

In the last few decades, advances in the cancer chemotherapy have been a marked success. A large number of anticancer drugs currently in use include drugs based on platinum complexes such as cisplatin, base analogues such as 5-florouracil and some ruthenium drugs. This review provides a bird’s eye view of interaction of a number of clinically important drugs currently in use that show covalent or non-covalent interaction with serum proteins. Platinum drug-cisplatin interacts covalently and alters the function of the key plasma protease inhibitor molecule -alpha-2-macroglobulin and induces the conformational changes in the protein molecule and inactivates it. 5-fluorouracil (5-FU) is extensively metabolized and at physiological concentrations, is found to be associated with Human Serum Albumin (HSA). Similarly ruthenium compounds bind tightly to plasma proteins- serum albumin and serum transferrin, modifying their biological activity and increasing the toxicity of drug to cancer cells. Insight into varied anticancer drug- protein interaction will go a long way in understanding in totality of the mechanism of action of any anticancer drug and its possible effects/side effects.

Keywords: Alpha-2-macroglobulin, cisplatin, 5-FU, chemotherapeutic drugs, plasma proteins, new dimensions.

Graphical Abstract


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy